The First Affiliated Hospital with Nanjing Medical University

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

306

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

36 drugs in development

Approved8

Phase 35

Phase 222

Phase 14

Preclinical11

By Therapeutic Area

top 6

Oncology

2854%

Immunology

510%

Cardiovascular

48%

Neurology

36%

Hematology

24%

Respiratory

24%

R&D Momentum

91/100

Pipeline Velocity

70/100

Trial Completion Rate

85/100

Pipeline Concentration

32/100

Pipeline Freshness

62/100

Strategic Signals

↗Active in Hematology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 11, 2026

Enrolling by invitation

Real-World Study of Cligabalin(HSK16149) for the Treatment of Rosacea

Jul 2, 2026

Recruiting

A Single-Arm, Proof-of-Concept Study of Dihydroartemisinin in Adults With Metabolic Associated Fatty Liver Disease

Earlier

Jun 27, 2026TrialA Prospective Study of MRD-Guided, Time-Limited Therapy With Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients

Jun 26, 2026TrialA Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-Term Recurrence After Adjuvant Therapy

Jun 26, 2026TrialClinicopathological Characteristics and Prognosis of Local Recurrence After Radical Mastectomy for Breast Cancer: A Prospective Cohort Study

Jun 26, 2026TrialAn Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(4 drugs)

—

Cardiovascular(4 drugs)

Hematology(2 drugs)

—

Hematology(2 drugs)

Immunology(5 drugs)

—

Immunology(5 drugs)

Infectious Disease(2 drugs)

—

Infectious Disease(2 drugs)

Metabolic & Endocrine(2 drugs)

—

Metabolic & Endocrine(2 drugs)

Nephrology(1 drug)

—

Nephrology(1 drug)

Neurology(3 drugs)

—

Neurology(3 drugs)

Oncology(28 drugs)

—

Oncology(28 drugs)

Respiratory(2 drugs)

—

Respiratory(2 drugs)

Unknown / Other(3 drugs)

—

Unknown / Other(3 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)